

BenevolentAI

Results of Annual General Meeting

London, UK, 30 June 2022: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, announces that, at its Annual General Meeting (“AGM”) held today, all resolutions were duly passed.

The voting results will shortly be made available on the Company’s website [General Meetings](#), where the full documentation regarding the AGM is also available.

ENDS

Contacts for BenevolentAI:

Mel Folahan – Deputy Company Secretary
cosec@benevolent.ai

Media:

Rajin Kang - VP Communications
rajin.kang@benevolent.ai

Investors:

Fleur Wood – VP Investor Relations
fleur.wood@benevolent.ai
investors@benevolent.ai

ABOUT BENEVOLENTAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of over 20 disease programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.